PBPK modeling and simulation in drug research and development

被引:0
|
作者
Xiaomei Zhuang [1 ]
Chuang Lu [2 ]
机构
[1] State Key Laboratory of Toxicology and Medical Countermeasures,Beijing Institute of Pharmacology and Toxicology
[2] Department of DMPK,Biogen,Inc.
关键词
PBPK; PK prediction; Absorption; Metabolism; Drug–drug interaction; Special population;
D O I
暂无
中图分类号
R96 [药理学];
学科分类号
100602 ; 100706 ;
摘要
Physiologically based pharmacokinetic(PBPK) modeling and simulation can be used to predict the pharmacokinetic behavior of drugs in humans using preclinical data.It can also explore the effects of various physiologic parameters such as age,ethnicity,or disease status on human pharmacokinetics,as well as guide dose and dose regiment selection and aid drug–drug interaction risk assessment.PBPK modeling has developed rapidly in the last decade within both the field of academia and the pharmaceutical industry,and has become an integral tool in drug discovery and development.In this mini-review,the concept and methodology of PBPK modeling are briefly introduced.Several case studies were discussed on how PBPK modeling and simulation can be utilized through various stages of drug discovery and development.These case studies are from our own work and the literature for better understanding of the absorption,distribution,metabolism and excretion(ADME) of a drug candidate,and the applications to increase efficiency,reduce the need for animal studies,and perhaps to replace clinical trials.The regulatory acceptance and industrial practices around PBPK modeling and simulation is also discussed.
引用
收藏
页码:430 / 440
页数:11
相关论文
共 50 条
  • [11] PBPK Modeling and Simulation and Therapeutic Drug Monitoring: Possible Ways for Antibiotic Dose Adjustment
    Ferreira, Abigail
    Lapa, Rui
    Vale, Nuno
    PROCESSES, 2021, 9 (11)
  • [12] Efficient drug development of oseltamivir capsules based on process control, bioequivalence and PBPK modeling
    Medeiros, Juliana J. S.
    Costa, Thiago M.
    Carmo, Mariana P.
    Nascimento, Diogo D.
    Lauro, Eduardo N. C.
    Oliveira, Camila A.
    Duque, Marcelo D.
    Prado, Livia D.
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2022, 48 (04) : 146 - 157
  • [13] Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label
    Reddy, Venkatesh Pilla
    Walker, Michael
    Sharma, Pradeep
    Ballard, Peter
    Vishwanathan, Karthick
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2018, 7 (05): : 321 - 330
  • [14] Prediction of Drug–Drug Interactions Between Opioids and Overdosed Benzodiazepines Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation
    Beihong Ji
    Shuhan Liu
    Ying Xue
    Xibing He
    Viet Hoang Man
    Xiang-Qun Xie
    Junmei Wang
    Drugs in R&D, 2019, 19 : 297 - 305
  • [15] A Workflow Example of PBPK Modeling to Support Pediatric Research and Development: Case Study with Lorazepam
    A. R. Maharaj
    J. S. Barrett
    A. N. Edginton
    The AAPS Journal, 2013, 15 : 455 - 464
  • [16] A Workflow Example of PBPK Modeling to Support Pediatric Research and Development: Case Study with Lorazepam
    Maharaj, A. R.
    Barrett, J. S.
    Edginton, A. N.
    AAPS JOURNAL, 2013, 15 (02): : 455 - 464
  • [17] Pediatric Cardiovascular Drug Development and Research: Integration of Modeling and Simulation as One Future Direction
    Laer, Stephanie
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2011, 58 (03) : 217 - 227
  • [18] Predicting Human Dermal Drug Concentrations Using PBPK Modeling and Simulation: Clobetasol Propionate Case Study
    van Osdol, William W.
    Novakovic, Jasmina
    Le Merdy, Maxime
    Tsakalozou, Eleftheria
    Ghosh, Priyanka
    Spires, Jessica
    Lukacova, Viera
    AAPS PHARMSCITECH, 2024, 25 (03)
  • [19] Model-based drug development: application of modeling and simulation in drug development
    Kim T.H.
    Shin S.
    Shin B.S.
    Journal of Pharmaceutical Investigation, 2018, 48 (4) : 431 - 441
  • [20] Predicting Human Dermal Drug Concentrations Using PBPK Modeling and Simulation: Clobetasol Propionate Case Study
    William W. van Osdol
    Jasmina Novakovic
    Maxime Le Merdy
    Eleftheria Tsakalozou
    Priyanka Ghosh
    Jessica Spires
    Viera Lukacova
    AAPS PharmSciTech, 25